The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
Sofia, Bulgaria, September 29, 2022 – According to the requirements of Art. 148b and Art. 100t of LPOS, “Sopharma” AD notifies that the Company received a shareholding notification from “Telso” AD, UIC 131176385 for a transaction with shares of the Company with settlement on September 29, 2022 with which “Telso” AD reaches 5% in the capital of “Sopharma” AD.
Sofia, Bulgaria, September 7, 2022 – According to the requirements of art. 100t of LPOS, “Sopharma” AD notifies that for August 2022 the Company recorded a decrease in sales of 12% compared to the same month of the previous year, incl. 6% increase in domestic sales and 21% decrease in export sales.
For the eight months since the beginning of the year the revenues from sales of products increase by 35%, incl. 37% increase of sales for the domestic market and 35% increase in export sales.